These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28126969)

  • 1. The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.
    Stadler N; Hasibeder A; Lopez PA; Teschner D; Desuki A; Kriege O; Weber ANR; Schulz C; Michel C; Heβ G; Radsak MP
    Haematologica; 2017 May; 102(5):e191-e194. PubMed ID: 28126969
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib inhibits proinflammatory functions of mature human neutrophils.
    Futosi K; Németh T; Pick R; Vántus T; Walzog B; Mócsai A
    Blood; 2012 May; 119(21):4981-91. PubMed ID: 22411867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival.
    Radsak MP; Salih HR; Rammensee HG; Schild H
    J Immunol; 2004 Apr; 172(8):4956-63. PubMed ID: 15067076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils.
    Reali E; Spisani S; Gavioli R; Lanza F; Moretti S; Traniello S
    Immunol Cell Biol; 1995 Jun; 73(3):234-8. PubMed ID: 7590896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA.
    Choi M; Rolle S; Rane M; Haller H; Luft FC; Kettritz R
    Kidney Int; 2003 Jan; 63(1):96-106. PubMed ID: 12472772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.
    Alflen A; Stadler N; Aranda Lopez P; Teschner D; Theobald M; Heß G; Radsak MP
    Sci Rep; 2018 Apr; 8(1):5558. PubMed ID: 29615799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
    Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal but not altered mucins activate neutrophils.
    Aknin ML; Berry M; Dick AD; Khan-Lim D
    Cell Tissue Res; 2004 Dec; 318(3):545-51. PubMed ID: 15490242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib: a paradigm shift in management of CLL.
    Badar T; Burger JA; Wierda WG; O'Brien S
    Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
    Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of high mobility group box 1 in the activation of C5a-primed neutrophils induced by ANCA.
    Wang C; Wang H; Hao J; Chang DY; Zhao MH; Chen M
    Clin Immunol; 2015 Jul; 159(1):47-57. PubMed ID: 25934387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oxidation state of phospholipids controls the oxidative burst in neutrophil granulocytes.
    Blüml S; Rosc B; Lorincz A; Seyerl M; Kirchberger S; Oskolkova O; Bochkov VN; Majdic O; Ligeti E; Stöckl J
    J Immunol; 2008 Sep; 181(6):4347-53. PubMed ID: 18768893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumor necrosis factor: separation of signals for the respiratory burst and degranulation.
    Han H; Fuortes M; Nathan C
    J Exp Med; 2003 Jan; 197(1):63-75. PubMed ID: 12515814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel immunomodulatory effect of ugonin U in human neutrophils via stimulation of phospholipase C.
    Chen CY; Liaw CC; Chen YH; Chang WY; Chung PJ; Hwang TL
    Free Radic Biol Med; 2014 Jul; 72():222-31. PubMed ID: 24747490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
    Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
    Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 4 plays an important role to enhance bacterial clearance from the nose in synergy with triggering receptor expressed on myeloid cells (TREM)-1 expression on polymorphonuclear neutrophils.
    Moriyama M; Hirano T; Kawano T; Kadowaki Y; Kodama S; Suzuki M
    Int J Pediatr Otorhinolaryngol; 2018 Sep; 112():27-33. PubMed ID: 30055735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
    Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
    Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
    Liu L; Shi B; Wang X; Xiang H
    Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.